JD Supra6d
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
The U.S. Food and Drug Administration (FDA) recently issued two new guidance documents governing details of the Accelerated Approval ...
Precise binding free energy calculations unlock new frontiers in drug design
Drug discovery is a costly and time-intensive process, with binding free energy calculations between the potential drug ...
Ocean Biomedical Advances Malaria Vaccine Research with New NIH Funding and Expedited Development Pathway
Ocean Biomedical (NASDAQ: OCEA) announced today that its Scientific Co-founder, Dr. Jonathan Kurtis, MD, PhD, and his research team have received additional significant funding from the National ...
FDA approves new pain drug Journavx as opioid alternative
Federal officials on Thursday approved a new type of pain drug designed to eliminate the risks of addiction and overdose ...
Turning Off Anxiety: Scientists Discover the Brain’s Hidden Switch
Scientists have pinpointed a brain circuit that, when activated, reduces anxiety without impairing memory. Using ...
labiotech12d
Curing ALS? Fourteen companies developing new treatments in 2025
Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...
Business Wire9d
Genialis Advances Biomarker Discovery to Reduce Risk in Cancer Drug Development Targeting DNA Damage Response Pathways
DDR is a promising arena for the development of precision medicines ... of biomarkers across the entire landscape of cancer drug targets, including DDR. Trained on hundreds of thousands of ...
Ocean Biomedical, Inc.: Ocean Biomedical Advances Malaria Vaccine Research with New NIH Funding and Expedited Development Pathway
Ocean Biomedical (NASDAQ: OCEA) announced today that its Scientific Co-founder, Dr. Jonathan Kurtis, MD, PhD, and his research team have received additional ...
Stockhead on MSN1d
Neurizon granted US patent for lead drug to treat motor neurone and other neurodegenerative conditions
A patent has been granted in the US covering the use of Neurizon’s lead drug candidate NUZ-001 in neurodegenerative diseases ...